Description

Poly(D,L-lactic acid)

Poly(D,L-lactic acid) (PDLLA) is a high-purity, amorphous, biodegradable polyester widely used in pharmaceutical controlled-release systems, implantable drug delivery devices, surgical implants, and tissue engineering scaffolds. Its tunable degradation profile, biocompatibility, and processability make it a critical excipient in long-acting drug formulations and advanced biomedical applications. PDLLA

• Is a pharmaceutical-grade amorphous biodegradable polyester
• Is fully biocompatible and hydrolytically degradable to lactic acid
• Supports injectable depots, microspheres, implants, and tissue scaffolds
• Offers adjustable degradation rates based on molecular weight and formulation design

Poly(D,L-lactic acid) is synthesized through ring-opening polymerization of D,L-lactide, producing a random copolymer of D- and L-lactic acid units that prevents crystallization, resulting in an amorphous structure. This amorphous nature provides greater flexibility in processing, drug incorporation, and controlled degradation compared to crystalline polylactic acid (PLA).

In pharmaceutical controlled-release formulations, PDLLA is widely used to produce microspheres, injectable depots, subcutaneous implants, and drug-eluting devices that release APIs over weeks to months. Its hydrolytic degradation into endogenous lactic acid supports biocompatibility and complete in vivo resorption without the need for surgical removal.

In biomedical and surgical applications, Poly(D,L-lactic acid) serves as a key material for resorbable sutures, orthopedic fixation devices, regenerative scaffolds, and bioresorbable wound healing materials, providing tailored mechanical support during tissue regeneration.

Pharmaceutical developers, medical device engineers, and procurement teams seeking to purchase Poly(D,L-lactic acid) benefit from CarboMer’s consistent manufacturing quality, tight molecular weight control, validated analytical methods, and global regulatory support.

Material is supplied in sealed, moisture-protected, tamper-evident packaging to ensure long-term stability. Minimum order quantities (MOQ), lead times, and comprehensive regulatory documentation are available to support clinical, commercial, and research programs.

Each batch undergoes rigorous analytical testing for molecular weight distribution, residual monomers, residual solvents, heavy metals, and microbial quality to ensure reproducibility and full regulatory compliance.

As with all CarboMer biomaterials and excipients, Poly(D,L-lactic acid) is supported by full technical consultation, formulation development support, and regulatory expertise to accelerate product development, scale-up, and global registration.